InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
Dec. 11, 2025 - InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received approval from the China National Medical Products Administration (NMPA) for the treatment of adult and adolescent patients (aged 12 years and older) with solid tumors harboring NTRK gene fusions.
December 12, 2025
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
Dec. 10, 2025 – InnoCare Pharma , a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of its novel BTK inhibitor orelabrutinib were presented at the 67th Annual Meeting of the American Society of Hematology (ASH).
December 10, 2025
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
Dec. 9, 2025 – InnoCare Pharma , a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced hat three studies of its novel BCL2 inhibitor, Mesutoclax (ICP-248), were presented at the 67th Annual Meeting of the American Society of Hematology (ASH). Mesutoclax demonstrated remarkable efficacy and a favorable safety profile in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and acute myeloid leukemia (AML).
December 10, 2025
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
Beijing, Nov. 28, 2025 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with prurigo nodularis in China.
November 28, 2025
From Cancer Titans to Metabolism Masters: Mapping the Therapeutic Identities of Top 13 Pharma Giants
An examination of the Q2 2025 sales breakdown across 13 major multinational pharmaceutical companies reveals a diverse set of therapeutic identities, shaped largely by revenue concentration in specific disease areas. While all these companies maintain some degree of portfolio diversification, the relative weight of therapeutic categories in their quarterly sales provides a clear window into their core business focus — whether in oncology, immunology, metabolism, vaccines, rare diseases, or other domains.
November 21, 2025
by N55.6761
Global Regulatory Trends in Monoclonal Antibody Development
Monoclonal antibodies (mAbs) represent one of the most innovative and rapidly advancing therapeutic classes in modern medicine, with applications across oncology, autoimmune and inflammatory disorders, infectious diseases, and rare conditions. These biologics are monospecific antibodies produced by identical immune cells cloned from a single parent cell through recombinant DNA technology. Their precisely controlled manufacturing, consistent structure, and reproducible affinity for specific antigens make them essential to the progress of precision medicine.
November 6, 2025
by Annie Roys
ESMO 2025: the Maturation of the ADC Modality
At the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, antibody–drug conjugates (ADCs) took center stage, not merely as incremental innovations but as a therapeutic class on the verge of redefining modern oncology. Across multiple sessions — from AstraZeneca’s presidential symposium to Merck’s and Bristol Myers Squibb’s early-phase showcases — ADCs demonstrated efficacy levels once reserved for targeted therapies or immuno-oncology breakthroughs. Response rates exceeding 50% in refractory populations, survival curves separating within months, and even signs of curative potential in early-stage disease signaled that the modality had reached a new clinical and technological maturity.
November 3, 2025
by N55.6761
InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
Beijing, October 31, 2025 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of its novel B7-H3 targeted ADC, ICP-B794, in China.
October 31, 2025
Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
Beijing, Oct. 30, 2025 – InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data of its next generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors. The data from the phase I/II clinical trial has been released at the Congress of International Society of Paediatric Oncology (SIOP) 2025 as an oral presentation.
October 30, 2025
Financing and Investment Strategies for Life Science Commercialization
This article explores financing/investment trends for life science commercialization, covering venture capital, public capital, partnerships, government incentives, and related risks.
October 11, 2025
by Annie Roys
InnoCare Pharma and Zenas BioPharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multip
InnoCare Pharma Limited and Zenas BioPharma, Inc. today announced a transformational license agreement granting Zenas global develop
October 8, 2025
by InnoCare Pharma
Drug Development: Latest Strategies to Fast-Track Innovation
The conventional drug development pipeline—from target discovery through clinical trials to regulatory approval—traditionally spans more than a decade and costs billions of dollars.
September 28, 2025
by Sadia Ajmal